Clinical Trials Browser

Interventional × Neoplasms × abemaciclib × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05386108 2026-02-05

ELECTRA

Phase 1/2 Recruiting

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT03310879 2025-09-02

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

Phase 2 Recruiting

38 enrolled

Tumor-Agnostic

Neoplasms

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast

Breast Neoplasms, Neoplasms

NCT04534283 2024-08-07

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Phase 2 Terminated

16 enrolled 11 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03339843 2024-03-15

MiMe-A

Phase 2 Completed

85 enrolled

GastrointestinalGenitourinaryGynecologic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasms, Urologic Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT02117648 2019-01-07

A Study of LY2835219 in Participants With Cancer

Phase 1 Completed

26 enrolled 11 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Clinical Trials

I-SPY

TAPUR

ELECTRA

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

MiMe-A

TAILOR

A Study of LY2835219 in Participants With Cancer